Allogeneic hematopoietic cell transplantation for multiple myeloma☆
References (45)
- et al.
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma
Blood
(1993) - et al.
Graft-versusmyeloma effect
Lancet
(1996) - et al.
Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
Blood
(1996) - et al.
Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy
Blood
(1996) - et al.
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
Blood
(1996) - et al.
Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease
Blood
(1991) - et al.
Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
Blood
(2000) - et al.
Magnetic resonance imaging of the spine in multiple myeloma
Lancet
(1987) - et al.
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
Blood
(1995) Usefulness of immunofixation electrophoresis in the clinical laboratory
Clin Lab Med
(1986)
Mixed hematopoietic chimerism after hematopoietic stem cell allografts
Transplant Proc
Graft-versusmyeloma effect: Proof of principle
Blood
Graft-versus-myeloma effect in two cases
Lancet
Induction of graft versus myeloma by donor lymphocyte infusions following allogeneic bone marrow transplant
Allogeneic bone marrow transplantation for multiple myeloma
Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma
J Nucl Med
Phase I–II study of 166holmium-DOTMP in combination with melphalan +/—total body irradiation (TBI) with autologous peripheral blood stem cell transplant (PBSCT) for patients with multiple myeloma (MM)
Syngeneic marrow transplantation in patients with multiple myeloma
Bone Marrow Transplant
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
N Engl J Med
Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graftversus-myeloma effect
Leukemia
Minimal residual disease after bone marrow transplantation for multiple myeloma: Evidence for cure in long-term survivors
Bone Marrow Transplant
Allogeneic stem cell transplants for multiple myeloma. Bologna experience
Cited by (42)
Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation
2020, Clinical Lymphoma, Myeloma and LeukemiaCitation Excerpt :These include daratumumab, an anti-CD38 antibody, and elotuzumab, an anti-SLAMF7 antibody.2 Patients can be considered for allogeneic hematopoietic cell transplantation (allo-HCT) as a curative-intent option for high-risk disease or as an upfront therapy (as tandem autologous/allo-HCT approach) for relapsed MM after failure of one or more lines of therapy, including ASCT.3-8 Most recently, consolidation with allo-HCT (tandem) after ASCT has shown favorable long-term outcomes in a postrelapse setting of patients with MM.9
SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents
2019, Clinical Lymphoma, Myeloma and LeukemiaCitation Excerpt :There is a strong rationale to investigate immunotherapeutic approaches for MM. Durable complete remissions (CRs) in MM were reported with allogeneic stem-cell transplantation (allo-SCT), and in some cases, relapses after allo-SCT were rescued by donor lymphocyte infusion.3-6 These results demonstrated that immunologic therapy in the form of a graft-versus-tumor effect, mediated primarily by T cells, was capable of conferring long-term control of this disease.
Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
2009, Seminars in HematologyCitation Excerpt :Moreover, further evidence for graft-versus-myeloma effects are the molecular remissions, prelude to possible cure, that are more commonly observed after myeloablative allografting as compared to autografting and that can occur in up to 50% of patients.27 The most frequently used myeloablative conditionings have included cyclophosphamide with total body irradiation or busulfan, or melphalan and total body irradiation.12-14,28,29 The unacceptably high treatment-related mortality of up to 60% has commonly restricted this approach to young, usually in their fifth decade, medically fit patients.12-14
- ☆
Supported in part by Grants No. CA-18029, CA-78902, CA-47748, CA-18221, CA-15704, CA-58576, CA-09319, and CA-09515 from the National Cancer Institute, and HL 36444 from the National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; the Jose Carreras Foundation Against Leukemia, Barcelona, Spain; and the Joseph Steiner Krebstifftung, Bern, Switzerland.